These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 35324835)

  • 21. An update on the molecular pathology of urinary bladder tumors.
    Yousef PG; Gabril MY
    Pathol Res Pract; 2018 Jan; 214(1):1-6. PubMed ID: 29254798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates.
    Solomon JP; Hansel DE
    Adv Anat Pathol; 2015 Mar; 22(2):102-12. PubMed ID: 25664945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Giridhar KV; Kohli M
    Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis.
    Wang X; MacLennan GT; Lopez-Beltran A; Cheng L
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):8-18. PubMed ID: 17536302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
    Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent advances in bladder urothelial carcinogenesis].
    Pignot G; le Goux C; Bieche I
    Bull Cancer; 2015 Dec; 102(12):1020-35. PubMed ID: 26617115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durvalumab in urothelial cancers.
    Lavaud P; Hamilou Z; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and epigenetic aspects of bladder cancer.
    Kim WJ; Quan C
    J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
    Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
    Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
    Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H
    Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of CA 125 in transitional cell carcinoma of the bladder.
    Manvar AM; Wallen EM; Pruthi RS; Nielsen ME
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1877-81. PubMed ID: 21110754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
    Xiao GQ; Barrett MM; Yang Q; Unger PD
    Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urine markers for detection and surveillance of bladder cancer.
    Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
    Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?].
    Erben P; Hartmann A; Bolenz C
    Aktuelle Urol; 2015 May; 46(3):227-35. PubMed ID: 26077307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapies in the management of metastatic bladder cancer.
    Fassan M; Trabulsi EJ; Gomella LG; Baffa R
    Biologics; 2007 Dec; 1(4):393-406. PubMed ID: 19707309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.
    Kawaguchi M; Hara N; Bilim V; Koike H; Suzuki M; Kim TS; Gao N; Dong Y; Zhang S; Fujinawa Y; Yamamoto O; Ito H; Tomita Y; Naruse Y; Sakamaki A; Ishii Y; Tsuneyama K; Inoue M; Itoh J; Yasuda M; Sakata N; Jung CG; Kanazawa S; Akatsu H; Minato H; Nojima T; Asai K; Miura Y
    BMC Cancer; 2016 Oct; 16(1):805. PubMed ID: 27756245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and molecular markers of urothelial premalignancy and malignancy.
    Cordon-Cardo C; Cote RJ; Sauter G
    Scand J Urol Nephrol Suppl; 2000; (205):82-93. PubMed ID: 11144907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.